Monitor ESMO 2026 presentation for any data updates on REO 033 enrollment or early signals. The pivotal expansion (Part B) and potential accelerated approval path are the next key catalysts, but no timeline is provided.
Price Chart
Executive Summary
Oncolytics Biotech announced a trial-in-progress abstract and e-poster for its REO 033 study of pelareorep in RAS-mutant MSS metastatic colorectal cancer at the ESMO 2026 Congress. The filing is a routine clinical-stage update with no new data, no financial figures, and no material change to the company's outlook.
Key Facts
- REO 033 is a randomized Phase 2 study evaluating pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab in 2L RAS-mutant MSS mCRC.
- The trial-in-progress abstract (e-poster #994eTiP) will be presented at ESMO 2026.
- Primary endpoint is ORR; secondary endpoints include OS, PFS, DCR, DOR, and safety.
- FDA interactions have provided opportunity for a potential pivotal expansion (Part B) that could support accelerated approval based on ORR and full approval based on PFS.
- Prior REO 022 study showed ORR, median PFS, median OS, and median DOR more than doubled vs historical controls.
- No financial data, revenue, or guidance was provided in the filing.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data from REO 033.
- Regulatory delays or negative FDA feedback on the accelerated approval pathway.
- Cash burn from ongoing clinical development without near-term revenue.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000074 |
| Document: oncyemso2026reo033tip.htm | 0001129928-26-000074 |
| Document: 0001129928-26-000074-index-headers.html | 0001129928-26-000074 |
| Document: 0001129928-26-000074-index.html | 0001129928-26-000074 |
| Document: 0001129928-26-000074.txt | 0001129928-26-000074 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.4858 | awaiting T+20 | — | $0.4623 (−4.84%) |
Oct 27, 2026 today | Press Release | $0.4700 | awaiting T+20 | — | $0.4623 (−1.64%) |
Oct 20, 2026 7d ago | 8-K | $0.4986 | awaiting T+20 | — | $0.4623 (−7.28%) |
Oct 20, 2026 7d ago | Press Release | $0.4986 | awaiting T+20 | — | $0.4623 (−7.28%) |
Oct 14, 2026 13d ago | 8-K | $0.5382 | awaiting T+20 | — | $0.4623 (−14.10%) |
Oct 13, 2026 14d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.4623 (−5.65%) |
Oct 6, 2026 21d ago | DEFA14A | $0.6000 | awaiting T+20 | — | $0.4623 (−22.95%) |
Oct 6, 2026 21d ago | DEF 14A | $0.6000 | awaiting T+20 | — | $0.4623 (−22.95%) |
Sep 29, 2026 28d ago | 8-K | $0.6745 $0.4623 | ▼ −31.46% | ▼ −32.17% | $0.4623 (−31.46%) |
Sep 28, 2026 29d ago | 8-K | $0.6630 $0.4732 | ▼ −28.63% | ▼ −28.60% | $0.4623 (−30.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers